vidarabine has been researched along with Osteogenic Sarcoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cole, PD; Kamen, BA; Smith, AK | 1 |
| Ijichi, O; Ikarimoto, N; Ishikawa, S; Kawano, Y; Kodama, Y; Manago, K; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T | 1 |
| Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
| ter Meulen, V | 1 |
1 review(s) available for vidarabine and Osteogenic Sarcoma
| Article | Year |
|---|---|
[Present state of antiviral therapy (author's transl)].
Topics: Amantadine; Antiviral Agents; Child; Cytarabine; Encephalitis; Herpes Simplex; Humans; Idoxuridine; Influenza, Human; Interferons; Keratitis, Dendritic; Osteosarcoma; Ribavirin; Smallpox; Thiosemicarbazones; Vidarabine | 1979 |
3 other study(ies) available for vidarabine and Osteogenic Sarcoma
| Article | Year |
|---|---|
Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Bone Neoplasms; Cattle; Culture Media; Cytarabine; Dialysis; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fetal Blood; Humans; Hypoxanthine; Methotrexate; Neoplasm Proteins; Nucleotides; Osteosarcoma; Tetrahydrofolate Dehydrogenase; Thymidine; Tumor Cells, Cultured; Vidarabine | 2002 |
Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.
Topics: Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Myeloablative Agonists; Osteosarcoma; Pleural Neoplasms; Radiography, Thoracic; Vidarabine | 2006 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |